Dublin, Aug. 30, 2018 (GLOBE NEWSWIRE) -- The "Advanced Drug Delivery Systems - A Global Market Overview" report has been added to ResearchAndMarkets.com's offering.

The report reviews, analyzes and projects the global Advanced Drug Delivery Systems market for the period 2015-2024 in terms of value in US$ and the compound annual growth rates (CAGRs) projected from 2017 through 2024.

Pharmaceutical companies have developed numerous therapeutic compounds that can address several life threatening ailments or disorders. The traditional dosage form offers spontaneous drug liberation that leads to drug concentration variation in the circulatory system. Hence to regulate the steady effective drug levels in the blood, introduction of Advanced Drug Delivery System is essential. Availability of the therapeutic compounds that are site specific, exhibit maximum therapeutic efficacy, capable of performing the same action in minimal dosage forms, increase in research and development protocols that aim to introduce maximum number of advanced drug delivery systems are some of the factors responsible for the growth of Advanced Drug Delivery Systems market. Research Findings & Coverage

  • Global Advanced Drug Delivery Systems market is analyzed in this report with respect to carrier types, route of administration and applications
  • Degradable Microneedle - Promising Future Injectable Drug Delivery System
  • Electrospun Based Nanofibers - A Novel Drug Delivery System
  • Reduction-Sensitive Polymer Nanomedicines - Future Targeted Drug Delivery Platform for Cancer
  • Platelets Serving as a Novel Drug Carrier
  • Key business trends focusing on product innovations/developments, M&As, JVs and other recent industry developments
  • Major companies profiled - 39
  • The industry guide includes the contact details for 204 companies

Key Topics Covered:

PART A: GLOBAL MARKET PERSPECTIVE 1. INTRODUCTION 1.1 Product Outline 1.1.1 Drug Delivery 1.1.1.1 Conventional Dosage Forms 1.1.1.1.1 Advantages of Conventional Dosage Forms 1.1.1.1.2 Disadvantages of Conventional Dosage Forms 1.1.1.2 Modified Release Drug Delivery System 1.1.1.2.1 Modified drug delivery systems Benefits include 1.1.1.2.2 Types of Non immediate Release Dosage Forms 1.1.2 Advanced Drug Delivery Systems 1.1.2.1 Advantages of Advanced Drug Delivery Systems over Conventional Systems 1.1.2.2 Carrier Types 1.1.2.2.1 Liposomes 1.1.2.2.2 Nanogels 1.1.2.2.3 Polymers 1.1.2.2.4 Monoclonal Antibodies 1.1.2.2.4.1 Antibody Drug Conjugates 1.1.2.2.5 Prodrugs 1.1.2.2.6 Albumin 1.1.2.2.7 Niosomes 1.1.2.2.8 Microparticles 1.1.2.3 Route of Administration 1.1.2.3.1 Oral Drug Delivery Systems 1.1.2.3.1.1 Chewing Gums 1.1.2.3.2 Parenteral Drug Delivery Systems 1.1.2.3.2.1 Needle Free Injection Technology 1.1.2.3.2.2 Autoinjector 1.1.2.3.3 Topical Drug Delivery System 1.1.2.3.3.1 Methods Employed To Improve the Topical Administration of Drug 1.1.2.3.4 Transdermal Patches 1.1.2.3.5 Implants 1.1.2.3.6 Nasal Drug Delivery 1.1.2.4 Advanced Drug Delivery Systems Applications 1.1.2.4.1 Oncology 1.1.2.4.1.1 Lipoprotein 1.1.2.4.1.2 Nanoparticles 1.1.2.4.1.3 Nanoemulsions 1.1.2.4.1.4 Microcapsules 1.1.2.4.1.5 Microemulsion 1.1.2.4.1.6 Microspheres 1.1.2.4.1.7 Dendrimers 1.1.2.4.2 Cardiovascular Diseases 1.1.2.4.3 Glaucoma 1.1.2.4.4 Multiple Sclerosis 1.1.2.4.5 Malaria Treatment 1.1.2.4.6 Research and Development 1.1.2.4.7 Tissue or Organ Transplantation 1.1.2.4.8 Gastrointestinal Disorder 1.1.2.4.9 Central Nervous Systems Ailments 1.1.2.4.10 Diabetes 1.1.2.4.11 Periodontal Diseases 2. KEY MARKET TRENDS 2.1 Self Fabricating Nanotubes - Potential Advanced Drug Delivery Channels 2.2 Sperm Tagged Drug as Advanced Drug Carrier to Treat Female Reproductive Ailments 2.3 Fluid Feeding Insects as a Replica to Design Advanced Drug Delivery Systems 2.4 Degradable Microneedle - Promising Future Injectable Drug Delivery System 2.5 Nanoparticles based Nasal Spray for Brain Disorders 2.6 Electrospun based Nanofibers - A Novel Drug Delivery System 2.7 Reduction-Sensitive Polymer Nanomedicines - Future Targeted Drug Delivery Platform for Cancer 2.8 Platelets Serving as a Novel Drug Carrier 2.9 Biomaterial Matrix as Growth Factors Carriers in Wound Healing Protocols 2.10 Anhydrous Nanoemulsions Acts as a Vehicle to Delivery Less Water Dissolvable Therapeutic Compounds 2.11 Nano and Micro Needles as an Advanced Transepidermal Drug Carrier 3. KEY GLOBAL PLAYERS

  • 3M Company (United States)
  • Adare Pharmaceuticals, Inc (United States)
  • Alkermes, Inc. (Ireland)
  • Astrazeneca PLC (United Kingdom)
  • Bayer AG (Germany)
  • Becton, Dickinson and Company (United States)
  • Capsugel, Inc. (United States)
  • Catalent, Inc. (United States)
  • Consort Medical PLC (United Kingdom)
  • Bespak Europe Ltd (United Kingdom)
  • Elixir Medical Corporation (United States)
  • Gerresheimer AG (Germany)
  • Sensile Medical AG (Switzerland)
  • Hisamitsu Pharmaceutical Co., Inc. (Japan)
  • HNS International, Inc. (United States)
  • Insulet Corporation (United States)
  • Lupin Ltd (India)
  • Nektar Therapeutics (United States)
  • Novavax, Inc. (United States)
  • SHL Group (Taiwan)

4. KEY BUSINESS & PRODUCT TRENDS

  • Omnipod System Now Available in British Columbia
  • Mundipharma and PharmaJet Join Forces to Distribute Needle Free Drug Delivery System
  • Introduction of Non Patented Exelon patch by Mylan
  • InsuJet Plans to Directly Distribute Omnipod Product portfolio in Europe
  • Release of KP415.E01 Efficacy and Safety Outcomes in ADHD Children by Kempharma
  • Successful Completion of Treprostinil Technosphere's phase I studies against PAH by Mannkind
  • Breakthrough Therapy Designation Honored to HTX-011 of Heron by FDA
  • SELFDOSETM injector of West Receives Silver MDEA
  • Establishment of Novel Alliances in Europe to Extend the Omnipod systems Availability
  • Ferring Paid Third Partial Payment for ZOMAJET to Antares
  • Indian Supply Contract signed between Mannkind and Cipla for Afrezza
  • MED TRUST and Valeritas signed a V-Go Supply Contract in Germany and Austria
  • Presentation of RSV F and NanoFlu Vaccines Clinical Data at World Vaccine Congress by Novavax
  • Valeritas signed a contract to Supply V-Go in Australia and New Zealand with AMSL Diabetes and NZMS
  • PharmaJet Announces Positive Outcomes for Phase I Hantavirus Vaccine Clinical Studies
  • Harvard and Novartis Joins Forces to Design Immunotherapy Drug Delivery System
  • Orphan Drug Status Allotted to ZENEO to treat Status Epilepticus
  • Movi SpA and Valeritas Entered into V-Go Italian Marketing Deal
  • Genexine and PharmaJet Join Forces to Develop DNA Vaccine
  • Expansion of HPV vaccine Human Clinical Studies by Vaccibody
  • FDA Clearance Granted to Kempharm's Apadaz
  • V-Go of Valeritas is Accessible in Puerto Rico Through Fusion Consulting Group
  • Invectys Initiates DNA Cancer Vaccine Phase II Studies in Association with PharmaJet
  • CINVANTITM of Heron Receives U.S. FDA Clearance for CINV
  • Elixir Introduces DynamXTM Stent
  • Lonza Emerges as a Major Integrated Solution Providing Entity after Acquiring Capsugel
  • Catalent Join Forces with Rutgers for Pediatric Drug Formulation and Delivery
  • Introduction of Needle Free MMR Vaccine by PharmaJet and Serum Institute
  • SUSTOL of Heron Adopted in NCCN Antiemesis Guidelines
  • 3M and Panacea Join Forces to Develop Novel Cancer Vaccine
  • Emergence of Avadel by the completion of Cross-Border Merger of Flamel
  • Bayer Partners with DelSiTech to Develop Ophthalmic Drug
  • PharmaJet Develops HPV Vaccine in Association with Vaccibody
  • SUSTOLTM of Heron Received U.S FDA Clearance to Treat Chemotherapy Related Nausea & Vomiting
  • Utilization of PharmaJet Device against Zika Virus by NIH
  • PharmaJet Signs a Multiyear Contract with WHO for Polio
  • PharmaJet Unites with Universities to Offer Needle-Less Flu Shots
  • Amgen Opts SmartDose Drug Delivery System of West for PushtronexTM
  • ELIGARD of TOLMAR Achieves FDA Clearance to store at Room Temperature Up To 56 Days
  • Launch of Novel Transdermal Release Line by 3M
  • Consort by acquiring Aesica Introduces a Novel Trade Name
  • AstraZeneca Employs DEP drug delivery platform of Starpharma for Cancer Drug

5. GLOBAL MARKET OVERVIEW 5.1 Global Advanced Drug Delivery Systems Market Overview by Carrier Type 5.1.1 Global Advanced Drug Delivery systems Carrier Type Market Overview by Geographic Region 5.1.1.1 Nanoparticles 5.1.1.2 Polymers 5.1.1.3 Monoclonal Antibodies 5.1.1.4 Other Carrier Types 5.2 Global Advanced Drug Delivery Systems Market Overview by Route of Administration 5.2.1 Global Advanced Drug Delivery systems Route of Administration Market Overview by Geographic Region 5.2.1.1 Oral 5.2.1.2 Parenteral 5.2.1.3 Topical 5.2.1.4 Other Routes of Administration 5.3 Global Advanced Drug Delivery Systems Market Overview by Application 5.3.1 Global Advanced Drug Delivery Systems Application Market Overview by Geographic Region 5.3.1.1 Oncology 5.3.1.2 Cardiology 5.3.1.3 Neurology 5.3.1.4 Pulmonary 5.3.1.5 Other Applications 6. NORTH AMERICA

Major Market Players

  • 3M Company (United States)
  • Adare Pharmaceuticals, Inc (United States)
  • Becton, Dickinson and Company (United States)
  • Capsugel, Inc. (United States)
  • Catalent, Inc. (United States)
  • Elixir Medical Corporation (United States)
  • Eyepoint Pharmaceuticals, Inc. (United States)
  • Heron Therapeutics, Inc. (United States)
  • HNS International, Inc. (United States)
  • Insulet Corporation (United States)
  • Kempharm, Inc. (United States)
  • Mannkind Corporation (United States)
  • Medical International Technologies (Mit Canada) Inc. (Canada)
  • Mylan Laboratories (United States)
  • National Medical Products, Inc. (United States)
  • Nektar Therapeutics (United States)
  • Novavax, Inc. (United States)
  • Noven Pharmaceuticals, Inc. (United States)
  • Pharmajet (United States)
  • Theraject, Inc. (United States)
  • Tolmar Pharmaceuticals, Inc. (United States)
  • Valeritas, Inc. (United States)
  • West Pharmaceutical Services, Inc. (United States)
  • Xel Pharmaceuticals, Inc. (United States)

7. EUROPE

Major Market Players

  • Alkermes, Inc. (Ireland)
  • Astrazeneca PLC (United Kingdom)
  • Bayer AG (Germany)
  • Consort Medical PLC (United Kingdom)
  • Bespak Europe Ltd (United Kingdom)
  • Crossject (France)
  • European Pharma Group BV (The Netherlands)
  • Gerresheimer AG (Germany)
  • Injex UK Ltd (United Kingdom)
  • Sensile Medical AG (Switzerland)
  • Skyepharma Production SAS (France)

8. ASIA-PACIFIC

Major Market Players

  • Hisamitsu Pharmaceutical Co., Inc. (Japan)
  • Kyoto Medical Planning Co., Ltd (Japan)
  • Lupin Ltd (India)
  • SHL Group (Taiwan)

9. REST OF WORLD

For more information about this report visit https://www.researchandmarkets.com/research/q...anced?w=12

CONTACT: ResearchAndMarkets.com Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Drug Delivery